C4 Therapeutics Earnings Estimate
| CCCC Stock | USD 2.70 0.08 2.88% |
C4 Therapeutics Earnings Estimation Breakdown
The calculation of C4 Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of C4 Therapeutics is estimated to be -0.28 with the future projection ranging from a low of -0.28 to a high of -0.28. Please be aware that this consensus of annual earnings estimates for C4 Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.28 Lowest | Expected EPS | -0.28 Highest |
C4 Therapeutics Earnings Projection Consensus
Suppose the current estimates of C4 Therapeutics' value are higher than the current market price of the C4 Therapeutics stock. In this case, investors may conclude that C4 Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and C4 Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 8 | 60.95% | 0.0 | -0.28 | -1.67 |
C4 Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of C4 Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering C4 Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of C4 Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.C4 Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as C4 Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of C4 Therapeutics should always be considered in relation to other companies to make a more educated investment decision.CCCC Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact C4 Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-02-25 | 2025-12-31 | -0.2886 | -0.18 | 0.1086 | 37 | ||
2025-11-06 | 2025-09-30 | -0.41 | -0.44 | -0.03 | 7 | ||
2025-07-30 | 2025-06-30 | -0.4 | -0.37 | 0.03 | 7 | ||
2025-05-06 | 2025-03-31 | -0.35 | -0.37 | -0.02 | 5 | ||
2025-02-20 | 2024-12-31 | -0.4504 | -0.49 | -0.0396 | 8 | ||
2024-10-31 | 2024-09-30 | -0.38 | -0.35 | 0.03 | 7 | ||
2024-08-01 | 2024-06-30 | -0.37 | -0.26 | 0.11 | 29 | ||
2024-05-08 | 2024-03-31 | -0.35 | -0.41 | -0.06 | 17 | ||
2024-02-22 | 2023-12-31 | -0.68 | -0.7 | -0.02 | 2 | ||
2023-11-01 | 2023-09-30 | -0.66 | -0.52 | 0.14 | 21 | ||
2023-08-08 | 2023-06-30 | -0.69 | -0.73 | -0.04 | 5 | ||
2023-05-04 | 2023-03-31 | -0.75 | -0.71 | 0.04 | 5 | ||
2023-02-23 | 2022-12-31 | -0.74 | -0.77 | -0.03 | 4 | ||
2022-11-03 | 2022-09-30 | -0.67 | -0.65 | 0.02 | 2 | ||
2022-08-04 | 2022-06-30 | -0.69 | -0.56 | 0.13 | 18 | ||
2022-05-05 | 2022-03-31 | -0.58 | -0.65 | -0.07 | 12 | ||
2022-02-24 | 2021-12-31 | -0.58 | -0.31 | 0.27 | 46 | ||
2021-11-10 | 2021-09-30 | -0.59 | -0.51 | 0.08 | 13 | ||
2021-08-11 | 2021-06-30 | -0.59 | -0.51 | 0.08 | 13 | ||
2021-05-13 | 2021-03-31 | -0.63 | -0.49 | 0.14 | 22 | ||
2021-03-11 | 2020-12-31 | -0.53 | -0.04 | 0.49 | 92 | ||
2020-11-12 | 2020-09-30 | -0.79 | -17.55 | -16.76 | 2121 | ||
2020-09-02 | 2020-06-30 | 0 | -0.1 | -0.1 | 0 |
About C4 Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of C4 Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current C4 Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as C4 Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -738.7 M | -701.8 M | |
| Retained Earnings Total Equity | -356.3 M | -374.1 M | |
| Earnings Yield | (0.66) | (0.63) | |
| Price Earnings Ratio | (1.51) | (1.58) | |
| Price Earnings To Growth Ratio | 0.09 | 0.10 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.67) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value - what C4 Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.